Biocon Financial Statements

Biocon (BIOCON) reported revenue of ₹169.27B in FY2026 with net income of ₹3.69B. Total assets stood at ₹636.51B. Net worth was ₹340.32B (₹34,032 Cr) and free cash flow was ₹1.96B.

Biocon Income Statement

Hover the chart icon for year-over-year change.

FY 2025 – FY 2026

Item	Chart	2025	2026
Revenue		152.62B	169.27B
Cost of Rev. Cost of Revenue		-51.98B	-56.91B
Gross Profit		100.64B	112.36B
SGA Sales, General & Admin		-68.98B	-77.81B
Op. Income Operating Income		14.79B	14.99B
PBT Profit Before Tax		18.87B	4.48B
Net Income		14.29B	3.69B
Dil. Shares Diluted Shares		1.20B	1.37B
Diluted EPS		8.46	2.82

Figures in ₹ — millions (M), billions (B), trillions (T). EPS is earnings per share.

Understanding the Income Statement

The income statement shows Biocon's revenue and expenses over a period. Revenue minus costs gives gross profit; after operating expenses, interest, and taxes, the remainder is net income. Diluted EPS divides net income by all shares that could exist if options and convertibles were exercised.

Biocon Balance Sheet

Hover the chart icon for year-over-year change.

FY 2025 – FY 2026

Item	Chart	2025	2026
Curr. assets Total current assets		162.86B	171.80B
Non-curr. assets Total non-current assets		425.11B	464.71B
Total assets		587.97B	636.51B
Curr. liabilities Total current liabilities		143.34B	140.69B
Non-curr. liab. Total non-current liabilities		167.51B	129.60B
Total liabilities		310.85B	270.29B
Total equity		277.13B	366.22B
Total liab. & eq. Total liabilities & equity		587.97B	636.51B

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding the Balance Sheet

The balance sheet captures Biocon's financial position at a point in time — what it owns (assets), what it owes (liabilities), and the residual value to shareholders (equity). Total assets always equals total liabilities plus equity.

Biocon Cash Flow Statement

Hover the chart icon for year-over-year change.

FY 2025 – FY 2026

Item	Chart	2025	2026
Net Income		14.29B	3.69B
Operating CF Cash flow Operating Activities		40.61B	19.94B
Capex Investments in PPE		-21.37B	-17.98B
Investing CF Cash flow Investing Activities		-2.34B	-20.82B
Dividend Paid		-829.00M	-908.00M
Financing CF Cash flow Financing Activities		-18.54B	-9.24B
Cash (start) Cash at beginning of period		9.20B	29.24B
Cash (end) Cash at end of period		29.24B	21.12B
FCF Free Cash Flow		19.25B	1.96B

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding Cash Flow

The cash flow statement tracks how Biocon's cash moves through operations, investing, and financing activities. Free cash flow — operating cash minus capital expenditure — shows what is available to return to shareholders.

Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: Mar-2026